Mexico Dimenhydrinate Market Analysis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MEXICO DIMENHYDRINATE MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MEXICO DIMENHYDRINATE MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 COUNTRY SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 CAUSE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 MEXICO DEMENHYDRINATE MARKET: REGULATORY SCENARIO

5.1 KEY REGULATORY INFORMATION

5.2 GOOD MANUFACTURING PRACTICES (GMP) INSPECTION

5.3 TIMELINE TO APPROVE A DRUG

6 SUMMARY WRITE UP (MEXICO)

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF ALLERGIC DISORDER

7.1.2 INCREASE IN VULERABLE GERIATIC POPULATIONS

7.1.3 WIDE RANGE OF PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER

7.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING

7.1.5 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION IN MEXICAN ATMOSPHERE

7.2 RESTRAINTS

7.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DIMENHYDRINATE

7.2.2 AVAILABILITY OF OTHER ANTIHISTAMINES

7.2.3 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS

7.3 OPPORTUNITIES

7.3.1 AWARENESS FOR USE OF OTC PRODUCTS

7.3.2 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING

7.4 CHALLENGES

7.4.1 INCREASE IN ABUSE POTENTIAL

7.4.2 INTELLECTUAL PROPERTYY RIGHTS LAW

8 MEXICO DIMENHYDRINATE MARKET, BY PRESCRIPTION TYPE

8.1 OVERVIEW

8.2 OVER-THE-COUNTER (OTC)

8.3 PRESCRIPTION DRUGS

9 MEXICO DIMENHYDRINATE MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 NAUSEA

9.2.1 NAUSEA, BY DOSAGE FORM

9.2.1.1 TABLETS

9.2.1.2 CHEWABLES

9.2.1.3 SYRUP

9.2.1.4 INJECTIONS

9.2.1.5 OTHERS

9.3 VOMITING

9.3.1 VOMITING, BY DOSAGE FORM

9.3.1.1 TABLETS

9.3.1.2 CHEWABLES

9.3.1.3 SYRUP

9.3.1.4 INJECTIONS

9.3.1.5 OTHERS

9.4 DIZZINESS

9.4.1 DIZZINES, BY DOSAGE FORM

9.4.1.1 TABLETS

9.4.1.2 CHEWABLES

9.4.1.3 SYRUP

9.4.1.4 INJECTIONS

9.4.1.5 OTHERS

9.5 INSOMNIA

9.5.1 INSOMNIA, BY DOSAGE FORM

9.5.1.1 TABLETS

9.5.1.2 CHEWABLES

9.5.1.3 SYRUP

9.5.1.4 INJECTIONS

9.5.1.5 OTHERS

9.6 ALLERGIES

9.6.1 ALLERGIES, BY DOSAGE FORM

9.6.1.1 TABLETS

9.6.1.2 CHEWABLES

9.6.1.3 SYRUP

9.6.1.4 INJECTIONS

9.6.1.5 OTHERS

9.7 OTHERS

10 MEXICO DIMENHYDRINATE MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.2.1 ORAL, BY TYPE

10.2.1.1 SWALLOW TABLETS

10.2.1.2 CHEWABLES

10.2.1.3 OTHERS

10.3 PARENTERAL

11 MEXICO DIMENHYDRINATE MARKET, BY DOSAGE FORM

11.1 OVERVIEW

11.2 TABLETS

11.3 CHEWABLES

11.3.1 CHEWABLES, BY FLAVOR

11.3.1.1 GINGER

11.3.1.2 ORANGE

11.3.1.3 GRAPE FLAVOR

11.3.1.4 OTHERS

11.4 SYRUP

11.5 INJECTIONS

11.6 OTHERS

12 MEXICO DIMENHYDRINATE MARKET, BY PRODUCT TYPE

12.1 OVERVIEW

12.2 BRANDED

12.3 GENERIC

13 MEXICO DIMENHYDRINATE MARKET, BY AGE

13.1 OVERVIEW

13.2 ADULT

13.3 GERIATRIC

13.4 CHILD

14 MEXICO DIMENHYDRINATE MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 STORE BASED RETAIL

14.2.1 PHARMACIES AND DRUG STORES

14.2.2 SUPERMARKET/HYPERMARKET

14.2.3 HOSPITAL PHARMACIES

14.2.4 CONVENIENCE STORE

14.2.5 SPECIALITY STORES

14.2.6 OTHERS

14.3 ONLINE BASED RETAIL

15 MEXICO DIMENHYDRINATE MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: MEXICO

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 JOHNSON & JOHNSON SA DE CV

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 PRESTIGE CONSUMER HEALTHCARE INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.2.4.1 ACQUISITION

17.3 CINFA LABORATORIES (SUBSIDIARY OF MUNDIPHARMA)

17.3.1 COMPANY SNAPSHOT

17.3.2 PRODUCT PORTFOLIO

17.3.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS